Stroke, considered a prominent non-communicable disease, has a substantial impact on mortality and disability rates in China. Owing to the increasing population, and growing prevalence of risk factors for ischemic stroke such as diabetes, hypertension, and hyperlipidemia, China’s stent retriever market is set to grow at a compound annual growth rate of about 10% between 2023 and 2033, forecasts GlobalData, a leading data and analytics company.

GlobalData’s latest report “Neurovascular Thrombectomy Devices Market Size By Segments, Share, Regulatory And Reimbursement, Procedures And Forecast To 2033,” reveals that China’s stent retriever market accounts for about 40% of the Asia-Pacific (APAC) market in 2023 due to the country’s steadily rising ischemic incident cases, which are anticipated to reach 2 million by 2033.

The increasing incidence of ischemic stroke cases has led to an increased need for more sophisticated stent retrievers. Against this background, the National Medical Products Administration (NMPA) in China recently approved Tigertriever revascularization device for the treatment of ischemic stroke. Rapid Medical asserts that the Tigertriever revascularization device is pioneering patient-specific solutions for the removal of brain blood clots, thereby advancing the treatment of ischemic stroke.

Shraddha Sapkal, Medical Devices Analyst at GlobalData, comments: “In the past few years, there has been an increase in the use of stent retrievers to treat ischemic strokes. However, most of the conventional stent retrievers have limitations such as difficulty navigating wire in delicate intracranial vessels, limited stretchability, and force per unit length, which remains a critical issue.”

The Tigertriever revascularization device excels beyond most of the conventional stents by addressing their limitations, offering doctors the capability to enhance their precision and control while performing procedures and managing unexpected challenges. This innovative approach shifts these procedures from passive to active, streamlining clot capture and potentially reducing the risk of blood vessel injury during clot removal, resulting in higher revascularization rates.

Sapkal concludes: “To sum it up, as stroke evolves as a serious medical concern, there is a pressing need for devices that offer good control, high safety, and efficacy. The evolution of innovative devices such as Tigertriever brings forth a promising future for managing ischemic stroke in China.”